Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496677 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01496677 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 28 participants.
The verdict
NCT01496677, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
To compare the pharmacokinetic (PK) profile of TR-700 in elderly subjects versus younger control subjects
Interventions
- DRUG TR-701 FA 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-01-17 |
| Est. Completion | 2012-02-28 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496677
The ClinicalTrials.gov registry entry for NCT01496677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TR-701 FA 200 mg is the first listed.
NCT01496677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496677 about?
NCT01496677 is a clinical study titled "Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects". To compare the pharmacokinetic (PK) profile of TR-700 in elderly subjects versus younger control subjects
What is the current status of trial NCT01496677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2012-01-17. Estimated completion is 2012-02-28.
What interventions are being tested in trial NCT01496677?
The interventions under investigation include: TR-701 FA 200 mg (DRUG).
Who is sponsoring clinical trial NCT01496677?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.